Character is everything. In people, in companies, and now in precision medicine. When Character Biosciences announced its Series B extension, pushing total financing past $110 million, it wasn’t just another biotech headline. It was a marker that polygenic diseases, the messy multigene conditions pharma has sidestepped for decades, might finally be meeting their match. Sanofi Ventures led the extension, joining a syndicate already stacked with aMoon Growth Fund, Luma Group, Bausch + Lomb, Innovation Endeavors, Catalio Capital Management, and S32. You don’t line up that roster unless the science has teeth and the market has appetite.
The foundation traces back to 2019, when Cheng Zhang, Ph.D., and Laura Carter, Ph.D., launched Clover Therapeutics before rebranding as Character Biosciences in 2022. Zhang, once the head of strategy and innovation at Pfizer China, now serves as CEO, while Carter, an expert in translational genomics, drives the science as CSO. Their vision is direct: reclassify heterogeneous diseases like age-related macular degeneration into genetically defined subtypes, target root drivers, and unlock new therapies. With dry AMD affecting over 12 percent of Americans over 40 and costing billions annually, the stakes could not be higher.
Their approach blends AI-powered modeling with genomics, EMRs, imaging, and physician input to map disease progression and intervention windows. A deep phenotyping engine reshapes not just patient cohorts but the diseases themselves. The infrastructure is HIPAA-compliant, cloud-native, and reinforced with patents pending in biomarker discovery. This isn’t theoretical biotech; it’s a machine built for scale.
The reach is already tangible. Character has partnered with more than 150 ophthalmology clinics, creating an observational cohort of over 6,500 patients. That data pipeline fuels a pipeline of its own: CTX114, a complement inhibitor for geographic atrophy, and CTX203, a lipid modulator for intermediate AMD, both slated to enter Phase 1/2 trials within a year. Add in their collaboration with Bausch + Lomb and the company is positioned to move from mapping disease to rewriting outcomes.
The team behind it is stacked. Alongside Zhang and Carter, Erik Karrer, Ph.D., drives drug discovery, and Kaila Smilen, MBA, shapes corporate strategy. New hires include Robert Kim, M.D., MBA, as Chief Medical Officer, Daniel Elgort, Ph.D., as Chief Data & Analytics Officer, Josh Buddle leading the clinical network, and Jessamyn Wead building people operations. On the board, Sanofi Ventures’ Jason Hafler brings investor weight and industry vision.
The fresh capital has a clear path: advance CTX114 and CTX203 through clinical proof, expand into glaucoma, scale the longitudinal research network, and develop companion diagnostics to sharpen trial enrollment. With dry AMD and glaucoma representing multibillion-dollar markets with glaring unmet needs, the impact could be profound.
Building Character isn’t just a name. It’s about the grind of stitching together patient data, locking in world-class partners, and raising the capital to convert AI and genomics into therapies that actually make it to trial. In a space where hype often outruns reality, Character Biosciences is proving what execution looks like.
